Pharmacist-driven aminoglycoside quality improvement program

Journal of Chemotherapy

Volumn 21, Issue 1, 2009, Pages 42-45

  Greenwood, Bonnie C ^a   Szumita, P M ^a   Lowry, C M ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b STRATTON VA MEDICAL CENTER   (United States)

Author keywords

Amikacin; Aminoglycoside; Clinical pharmacist; Cystic fibrosis; Gentamicin; High dose Extended interval Aminoglycoside Therapy (HEAT); Quality improvement; Tobramycin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; TOBRAMYCIN;

ADULT; ARTICLE; BACTEREMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYSTIC FIBROSIS; DRUG DOSE REGIMEN; DRUG QUALITY; FEMALE; HEALTH CARE QUALITY; HUMAN; INCIDENCE; INTERVENTION STUDY; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OPTIMAL DRUG DOSE; OTOTOXICITY; PHARMACIST; PNEUMONIA; PROGRAM DEVELOPMENT; QUALITY CONTROL; URINARY TRACT INFECTION;

EID: 63049085604     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.1.42     Document Type: Article

References (17)

1. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31(7): 1054-1060.
2. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998; 27: 23-27.
3. Barger A, Fuhst C, Wiedemann B. Pharmacological indices in antibiotic therapy. J Antimicrob Chemother. 2003; 52(6): 893-898.
4. Chuck SK, Raber SR, Rodvold KA, Areff D. National survey of extended interval aminoglycoside dosing. Clin Infect Dis 2000; 30(3): 433-439.
5. Vanko JA, Brown BA, Fanikos J, Churchill W. Evaluation of implementing aminoglycoside dosing guidelines in a large academic medical center. Presented at the 39th ASHP Midyear Clinical Meeting and Exhibition, Orlando, FL; Dec 5-9, 2004.
6. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39(3): 650-655.
7. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39: 677-686.
8. Barza M, Ioannidis JP, Cappalleri JC, Lau J. Single or multiple daily doses of aminoglycosides: A meta-analysis. BMJ 1996; 312(10): 338-344.
9. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. An Intern Med 1996; 124(8): 717:725.
10. Wright AJ, Wilson WR, Matsumoto JY, et al. Influence of gentamicin dose size on efficacies of combinations of gentamicin and penicillin in experimental streptomycin-resistant enterococcal endocarditis. Antimicrob Agents Chemother 1982; 22(6): 972-975.
11. Graham JC, Gould FK. Role of aminoglycosides in the treatment of bacterial endocarditis. J Antimicrob Chemother 2002; 49(3): 437-444.
12. Smyth A, Tan KK, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomized controlled trial. Lancet 2005; 365(9459): 547-558.
13. Bates RD, Nahata MC, Jones JW, McCoy K, Young G, Cox S, et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest 1997; 112: 1208-1213.
14. Whithead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 2002; 19: 303-309.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31-41.
16. Davis DA, Taylor-Vaisy A. Translating guidelines into practice: A systematic review of theoretic concepts, practical experience and research in the adoption of clinical practice guidelines. CMAJ 1997; 157(4): 408-416.
17. Anger KE, Szumita PM. Barriers to glucose control in the ICU. Pharmacotherapy 2006; 26(2): 214-228.